People living with moderate-to-severe COPD prefer improvement of daily symptoms over the improvement of exacerbations: a multicountry patient preference study

Author:

Cook Nigel S.ORCID,Criner Gerard J.,Burgel Pierre-RégisORCID,Mycock Katie,Gardner Tom,Mellor Phil,Hallworth Pam,Sully Kate,Tatlock Sophi,Klein Beyza,Jones Byron,Le Rouzic Olivier,Adams Kip,Phillips Kirsten,McKevitt Mike,Toyama KazukoORCID,Gutzwiller Florian S.ORCID

Abstract

IntroductionThis patient preference study sought to quantify the preferences of people living with COPD regarding symptom improvement in the UK, USA, France, Australia and Japan.MethodsThe inclusion criteria were people living with COPD aged 40 years or older who experienced ≥1 exacerbation in the previous year with daily symptoms of cough and excess mucus production. The study design included: 1) development of an attributes and levels grid through qualitative patient interviews; and 2) implementation of the main online quantitative survey, which included a discrete choice experiment (DCE) to allow assessment of attributes and levels using hypothetical health state profiles. Preference weights (utilities) were derived from the DCE using hierarchical Bayesian analysis. A preference simulator was developed that enabled different health state scenarios to be evaluated based on the predicted patient preferences.Results1050 people living with moderate-to-severe COPD completed the survey. All attributes were considered important when patients determined their preferences in the DCE. In a health state preference simulation, two hypothetical health states (comprising attribute levels) with qualitatively equivalent improvements in A) cough and mucus and B) shortness of breath (SOB) resulted in a clear preference for cough and mucus improved profile. When comparing two profiles with C) daily symptoms improved and D) exacerbations improved, there was a clear preference for the daily symptoms improved profile.ConclusionsPeople living with moderate-to-severe COPD prefer to reduce cough and mucus production together over improvement of SOB and would prefer to reduce combined daily symptoms over an improvement in exacerbations.

Funder

Novartis Pharma AG, Basel, Switzerland

Publisher

European Respiratory Society (ERS)

Subject

Pulmonary and Respiratory Medicine

Reference46 articles.

1. US Food and Drug Administration . Patient Preference Information – Voluntary Submission, Review in Premarket Approval Applications, Humanitarian Device Exemption Applications, and De Novo Requests, and Inclusion in Decision Summaries and Device Labeling. Guidance for Industry, Food and Drug Administration Staff and Other Stakeholders. Silver Spring, Center for Devices and Radiological Health, 2016.

2. Cowie L , Bouvy J . Measuring patient preferences. 2019. https://www.myeloma.org.uk/wp-content/uploads/2019/07/NICE-Patient-Preferences-Report.pdf

3. FDA reported use of patient experience data in 2018 drug approvals;Kieffer;Ther Innov Regul Sci,2020

4. G lobal Initiative for Chronic Obstructive Lung Disease (GOLD) . Global Strategy for the Diagnosis, Management and Prevention of COPD. 2020. Available from: https://goldcopd.org/

5. Impact of cough and mucus on COPD patients: primary insights from an exploratory study with an Online Patient Community;Cook;Int J Chron Obstruct Pulmon Dis,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3